When the question of joint replacement first comes up

Being told that joint replacement may be on the horizon rarely means it needs to happen now. For most people, that conversation marks the start of a period — often months, sometimes years — in which the direction of travel can still be influenced.

What matters is where the joint sits in that trajectory. A focal area of cartilage damage confirmed on MRI, in a joint that still has meaningful space between the bones, represents a window in which a regenerative approach has genuine biological rationale. ChondroFiller®, an injectable collagen scaffold placed under ultrasound guidance in a 30–45 minute outpatient appointment, is positioned clinically as a first-line option at exactly this stage — not something to consider after every other route has been exhausted.

The honest question is not whether joint replacement can be avoided for life. It is whether the joint can be preserved well enough that replacement, if it does become necessary, remains a future decision rather than an immediate one. That distinction is what makes timing matter — and what makes early specialist assessment worth pursuing.

Why cartilage damage tends to progress without treatment

Articular cartilage — the smooth tissue lining joint surfaces — has no blood supply of its own. Without vessels to deliver repair cells and oxygen, even a small focal defect cannot heal the way a skin wound can. The body produces no meaningful cartilage replacement in response to damage; the defect stays, or slowly widens.

That limitation has a direct consequence for timing. The synovium and subchondral bone immediately surrounding a defect contain progenitor cells — the raw material any regenerative scaffold must recruit in order to form new tissue. As the defect expands and joint-space narrows, the quality and density of that surrounding cell population diminishes. Each increment of additional wear reduces the biological substrate available to respond to treatment.

The endpoint of this progression is bone-on-bone contact: a joint in which cartilage has been lost entirely and the structural architecture needed to anchor and integrate a scaffold no longer exists. At that stage, injectable repair is not appropriate — the conditions it depends on are gone.

Clinical guidance therefore frames MRI-confirmed focal defects — damage that is real but contained, in a joint that still retains meaningful space — as the point at which intervention carries the strongest biological rationale. Acting while that substrate is intact preserves the conditions that make repair possible.

How ChondroFiller works as an injectable scaffold

ChondroFiller® is a CE-marked Class III medical device: a scaffold made from Type I collagen, injected into the affected joint under ultrasound guidance in an outpatient setting. No incision, no general anaesthetic, and no operating theatre are involved.

Once placed, the liquid collagen gels within approximately 3–5 minutes, conforming to the geometry of the defect. The resulting porous structure functions as an open lattice, drawing the body's own repair cells inward to begin forming new cartilage — a process known as acellular matrix-induced chondrogenesis. In plain terms: the scaffold itself contains no added cells, but its architecture actively recruits the patient's own progenitor cells to do the repair work.

Over the following 12–24 months, the collagen framework is gradually resorbed as the body fills the space with regenerated tissue. By the time the scaffold has broken down completely, it has been replaced by the patient's own cartilage. That process is what sets ChondroFiller® apart from injections such as hyaluronic acid or corticosteroid, which address symptoms without targeting the structural defect itself. Neither of those options is without value in the right context, but neither promotes endogenous repair at the tissue level.

The injectable form carries no ceiling on defect size — it can coat the entire articular surface rather than requiring a precisely bounded lesion with a healthy surrounding rim. That said, suitability depends on whether sufficient residual joint architecture remains to support the repair process; the scaffold integrates with existing tissue, so there needs to be enough of it present.

What the clinical evidence shows

Published outcome data span three joints and more than 19,000 cases globally — an unusually broad base for a scaffold at this stage of clinical adoption.

Knee. The Jerosch et al. prospective post-market clinical follow-up study recorded a mean IKDC score improvement of 32.4 points, sustained and slightly increased at three-year follow-up. The Minimal Clinically Important Difference threshold for IKDC is 16.7 points, so this result is roughly double that benchmark. MOCART MRI scores — which capture structural repair quality on imaging — improved from 65.3 at four weeks to 81.6 at one year, stabilising in the 81.6–84.3 range, indicating progressive defect filling and good integration into surrounding native cartilage.

Hip. In prospective hip follow-up, Harris Hip Score improved by approximately 33 points.

Wrist. A 2025 study published in PMC examined ChondroFiller® in intra-articular distal radius fractures. At follow-up arthroscopy, treated patients showed statistically superior cartilage quality: median Outerbridge score 1.5 versus 3 in controls (P=0.006) and ICRS score 1 versus 3 (P=0.002), with no significant difference in complications.

Safety in context. Across published series, ChondroFiller® shows approximately 0% complication rate and a 3–8% reoperation rate. By comparison, microfracture carries reoperation rates of up to 41%, and ACI/MACI up to 37%.

What the evidence does not yet include. No large randomised controlled trial has measured arthroplasty avoidance as a primary endpoint. The case that ChondroFiller® may delay or reduce the need for joint replacement rests on multi-joint clinical outcome data and the biological rationale described in earlier sections — not on a direct head-to-head comparison against replacement surgery — which means individual suitability remains a matter for specialist clinical assessment.

Who is likely to benefit — and who is not

Three broad groups tend to arise in specialist assessments, and knowing roughly where you sit helps frame the conversation.

Likely suitable. The clearest candidates are patients with MRI-confirmed focal cartilage damage where the joint space is still present and the surrounding tissue remains intact — typically early-to-moderate osteoarthritis or a post-injury defect. Crucially, there is no upper age limit and no ceiling on defect size for the injectable form. Patients in their 60s or 70s who have been advised that joint replacement is approaching may still be assessed as candidates, with ChondroFiller® functioning as a joint-preservation step before replacement rather than as an alternative to it indefinitely.

Not suitable. Where arthritis has reached bone-on-bone end stage — where the structural substrate for scaffold integration has been lost — the injectable cannot substitute for joint replacement. The scaffold needs living tissue to work with; if that tissue is no longer present in sufficient quantity, the biological process cannot proceed.

The grey area. A good proportion of patients fall between these positions. Clinical guidance frames proceeding directly to surgery in a patient with a focal MRI-confirmed defect as over-treatment. Equally, prolonging the wait beyond the viable treatment window is not the aim. The specialist weighs MRI findings, symptom severity, activity level, and overall joint health to determine where that line sits — a judgement that depends on the individual's anatomy and trajectory, not a checklist any article can replicate.

Finding a specialist who offers ChondroFiller injection

Whether ChondroFiller® can delay joint replacement depends on timing, joint health, and individual anatomy — questions that require a specialist who offers the treatment and understands the full clinical picture. Availability varies across the UK, so identifying a practitioner with specific experience in injectable scaffold therapy is a practical first step.

Useful questions to raise at an initial assessment:

• Does my MRI show sufficient residual tissue for scaffold integration?
• What stage of cartilage damage am I at, and how does that affect timing?
• What outcome measures — IKDC, MOCART, pain scores — will be used to assess whether treatment is working?
• If my joint progresses, what would the pathway look like from here?

Search MSK lists specialists across the UK who offer ChondroFiller® / Liquid Cartilage™ injection — filter by region and specialty to find one near you.